Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PRAVEEN KUMAR TUMULA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1447402896
CMS profile
746364
Location
AMARILLO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$340.16

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $179.92 3
Food and Beverage $160.24 3

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Epizyme, Inc., $125.00 1
Seagen Inc. $95.00 1
Incyte Corporation $60.99 1
Myovant Sciences Inc. $23.93 1
Amgen Inc. $21.12 1
JAZZ PHARMACEUTICALS INC. $14.12 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PRAVEEN KUMAR TUMULA

NPI 1447402896 · CMS profile ID 746364

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

AMARILLO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447402896?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447402896?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447402896?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1447402896?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $340.16 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Epizyme, Inc., $125.0011/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832343341 CMS
JAZZ PHARMACEUTICALS INC. $14.1211/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845605919 CMS
Seagen Inc. $95.0006/08/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832188317 CMS
Incyte Corporation $60.9905/03/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835550457 CMS
Myovant Sciences Inc. $23.9304/14/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834994241 CMS
Amgen Inc. $21.1201/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826537917 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,168.66 28
PY2020 $4,815.65 8
PY2021 $340.16 6
PY2022 $1,916.32 26
PY2023 $4,540.57 16
PY2024 $2,679.61 6
PY2025 $6,258.84 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $604,557.82 36
PY2024 Principal investigator $1,085,444.24 161
PY2023 Principal investigator $684,815.25 77
PY2022 Principal investigator $638,195.90 127
PY2021 Principal investigator $416,830.90 164
PY2020 Principal investigator $201,522.62 122
PY2019 Recipient $1,287.72 1
PY2019 Principal investigator $54,363.67 98

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

77 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 BeiGene, Ltd. $60,573.60 12/21/2023 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1043117933
Principal investigator 1 Genentech, Inc. $1,125.00 12/15/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040609889
Principal investigator 1 Genentech, Inc. $3,998.00 12/13/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040610143
Principal investigator 1 Genentech, Inc. $2,857.00 12/13/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040610491
Principal investigator 1 Incyte Corporation $452.00 12/07/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040808257
Principal investigator 1 Incyte Corporation $226.00 12/07/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040808457
Principal investigator 1 Novartis Pharmaceuticals Corporation $26,161.00 12/05/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase No dispute reported 06/30/2026 1017237153
Principal investigator 1 Epizyme, Inc. $1,125.00 12/04/2023 Non-covered Recipient Entity
Us Oncology Research
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 980958031
Principal investigator 1 Incyte Corporation $50.00 11/22/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040808233
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $238.00 11/15/2023 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Connect MM The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 1027455415
Principal investigator 1 Genentech, Inc. $3,107.00 11/03/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040609563
Principal investigator 1 Genentech, Inc. $108.20 11/03/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040609581
Principal investigator 1 BeiGene, Ltd. $50,478.00 10/17/2023 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1043116693
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,666.00 10/15/2023 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Connect MM The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 1027455391
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $251.00 10/15/2023 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Connect MM The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 1027455401
Principal investigator 1 Genentech, Inc. $79.00 10/06/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040609225
Principal investigator 1 Genentech, Inc. $4,170.00 09/20/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040608765
Principal investigator 1 Incyte Corporation $489.00 09/15/2023 Non-covered Recipient Entity
TX ONC : AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040656119
Principal investigator 1 Incyte Corporation $489.00 09/15/2023 Non-covered Recipient Entity
TX ONC : AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040656135
Principal investigator 1 Incyte Corporation $489.00 09/15/2023 Non-covered Recipient Entity
TX ONC : AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040656153
Principal investigator 1 Incyte Corporation $489.00 09/15/2023 Non-covered Recipient Entity
TX ONC : AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040656169
Principal investigator 1 Incyte Corporation $489.00 09/15/2023 Non-covered Recipient Entity
TX ONC : AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040656185
Principal investigator 1 Incyte Corporation $489.00 09/15/2023 Non-covered Recipient Entity
TX ONC : AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040656203
Principal investigator 1 Incyte Corporation $489.00 09/15/2023 Non-covered Recipient Entity
TX ONC : AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040656219
Principal investigator 1 Incyte Corporation $489.00 09/15/2023 Non-covered Recipient Entity
TX ONC : AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040656235
Principal investigator 1 Incyte Corporation $489.00 09/15/2023 Non-covered Recipient Entity
TX ONC : AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040656251
Principal investigator 1 Incyte Corporation $489.00 09/15/2023 Non-covered Recipient Entity
TX ONC : AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040656267
Principal investigator 1 Incyte Corporation $489.00 09/15/2023 Non-covered Recipient Entity
TX ONC : AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040656283
Principal investigator 1 Incyte Corporation $489.00 09/15/2023 Non-covered Recipient Entity
TX ONC : AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040656301
Principal investigator 1 Genentech, Inc. $53.00 09/13/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040608619
Principal investigator 1 Genentech, Inc. $15,224.00 09/06/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040608501
Principal investigator 1 Genentech, Inc. $5,308.00 09/06/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040608585
Principal investigator 1 Genentech, Inc. $1,462.00 08/25/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040607837
Principal investigator 1 Genentech, Inc. $26.00 08/25/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040607949
Principal investigator 1 Genentech, Inc. $1,125.00 08/25/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040608013
Principal investigator 1 Genentech, Inc. $182.00 08/25/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040608171
Principal investigator 1 Genentech, Inc. $14,814.00 08/02/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040607539
Principal investigator 1 BeiGene, Ltd. $50,478.00 07/25/2023 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1043044807
Principal investigator 1 Epizyme, Inc. $1,125.00 07/24/2023 Non-covered Recipient Entity
Us Oncology Research
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 980949867
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,104.20 07/11/2023 Non-covered Recipient Entity
TEXAS ONCO AMARILLO
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase No dispute reported 06/30/2026 1017210729
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,236.46 07/11/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY EL PASO CANCER TREATMENT CENTER GATEWAY
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase No dispute reported 06/30/2026 1017218861
Principal investigator 1 Genentech, Inc. $632.00 06/28/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040605197
Principal investigator 1 Genentech, Inc. $1,125.00 06/28/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040605213
Principal investigator 1 Celgene Corporation $238.00 06/15/2023 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 1026488977
Principal investigator 1 Incyte Corporation $426.11 06/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040807869
Principal investigator 1 Genentech, Inc. $3,000.00 06/05/2023 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
CLL 1L Fit GV FCR BR No dispute reported 06/30/2026 1040573811
Principal investigator 1 BeiGene, Ltd. $50,478.00 05/02/2023 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1043045555
Principal investigator 1 Genentech, Inc. $11,979.00 04/26/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040604429
Principal investigator 1 Incyte Corporation $850.00 04/15/2023 Non-covered Recipient Entity
TX ONC : AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040656103
Principal investigator 1 Epizyme, Inc. $1,125.00 04/12/2023 Non-covered Recipient Entity
Us Oncology Research
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 980950181
Principal investigator 1 Incyte Corporation $1,721.67 03/29/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040807685
Principal investigator 1 Celgene Corporation $714.00 03/15/2023 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 1026489011
Principal investigator 1 Epizyme, Inc. $1,125.00 03/08/2023 Non-covered Recipient Entity
Us Oncology Research
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 980952699
Principal investigator 1 Epizyme, Inc. $1,125.00 03/08/2023 Non-covered Recipient Entity
Us Oncology Research
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 980955175
Principal investigator 1 Epizyme, Inc. $1,125.00 03/08/2023 Non-covered Recipient Entity
Us Oncology Research
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 980955225
Principal investigator 1 Epizyme, Inc. $1,125.00 03/08/2023 Non-covered Recipient Entity
Us Oncology Research
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 980955251
Principal investigator 1 Epizyme, Inc. $1,125.00 03/08/2023 Non-covered Recipient Entity
Us Oncology Research
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 980955269
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,095.53 03/08/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY EL PASO CANCER TREATMENT CENTER GATEWAY
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase No dispute reported 06/30/2026 1017219291
Principal investigator 1 Epizyme, Inc. $1,125.00 03/06/2023 Non-covered Recipient Entity
Us Oncology Research
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 980955041
Principal investigator 1 Incyte Corporation $7,460.57 03/03/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040807625
Principal investigator 1 Incyte Corporation $8,034.46 03/03/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040807651
Principal investigator 1 Incyte Corporation $1,000.00 03/03/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040807711
Principal investigator 1 Celgene Corporation $766.00 02/15/2023 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 1026488983
Principal investigator 1 Celgene Corporation $714.00 02/15/2023 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 1026489021
Principal investigator 1 Celgene Corporation $714.00 02/15/2023 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 1026489035
Principal investigator 1 Genentech, Inc. $1,125.00 02/09/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040606213
Principal investigator 1 Genentech, Inc. $1,125.00 02/09/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040606229
Principal investigator 1 Genentech, Inc. $5,604.00 02/09/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040606261
Principal investigator 1 BeiGene, Ltd. $50,478.00 02/07/2023 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1043046283
Principal investigator 1 Genentech, Inc. $9,000.00 02/01/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MorningSun No dispute reported 06/30/2026 1040605821
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,012.00 02/01/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase No dispute reported 06/30/2026 1017239985
Principal investigator 2 Celgene Corporation $5,500.00 01/18/2023 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Connect MDS/AML - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry: The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and tr No dispute reported 06/30/2026 1026488963
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,058.60 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community No dispute reported 06/30/2026 991125823
Principal investigator 1 Celgene Corporation $4,522.00 01/15/2023 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 1026488921
Principal investigator 1 Incyte Corporation $850.00 01/15/2023 Non-covered Recipient Entity
TX ONC : AMARILLO
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 1040656087
Principal investigator 1 Seagen Inc. $956.00 01/15/2023 Non-covered Recipient Entity
Texas Oncology-Amarillo
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression No dispute reported 06/30/2026 995897735
Principal investigator 1 Novartis Pharmaceuticals Corporation $233,090.85 01/10/2023 Non-covered Recipient Entity
TEXAS ONCO AMARILLO
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase No dispute reported 06/30/2026 1017209693